Logo image of CRON

CRONOS GROUP INC (CRON) Stock Fundamental Analysis

NASDAQ:CRON - CA22717L1013 - Common Stock

2.55 USD
+0.07 (+2.82%)
Last: 9/9/2025, 4:39:12 PM
2.54 USD
-0.01 (-0.39%)
After Hours: 9/9/2025, 4:39:12 PM
Fundamental Rating

5

Overall CRON gets a fundamental rating of 5 out of 10. We evaluated CRON against 195 industry peers in the Pharmaceuticals industry. CRON has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, CRON is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

CRON had positive earnings in the past year.
In the past year CRON had a positive cash flow from operations.
In the past 5 years CRON reported 4 times negative net income.
CRON had negative operating cash flow in 4 of the past 5 years.
CRON Yearly Net Income VS EBIT VS OCF VS FCFCRON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

1.2 Ratios

The Return On Assets of CRON (1.57%) is better than 83.59% of its industry peers.
With an excellent Return On Equity value of 1.71%, CRON belongs to the best of the industry, outperforming 81.54% of the companies in the same industry.
Industry RankSector Rank
ROA 1.57%
ROE 1.71%
ROIC N/A
ROA(3y)-5.62%
ROA(5y)-9.8%
ROE(3y)-5.87%
ROE(5y)-10.3%
ROIC(3y)N/A
ROIC(5y)N/A
CRON Yearly ROA, ROE, ROICCRON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

1.3 Margins

CRON has a better Profit Margin (14.19%) than 88.72% of its industry peers.
In the last couple of years the Profit Margin of CRON has declined.
CRON has a Gross Margin (32.74%) which is comparable to the rest of the industry.
Industry RankSector Rank
OM N/A
PM (TTM) 14.19%
GM 32.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-62.81%
GM growth 3YN/A
GM growth 5YN/A
CRON Yearly Profit, Operating, Gross MarginsCRON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K

More info and screens

8

2. Health

2.1 Basic Checks

CRON does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CRON has more shares outstanding
Compared to 5 years ago, CRON has more shares outstanding
CRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRON Yearly Shares OutstandingCRON Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
CRON Yearly Total Debt VS Total AssetsCRON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

An Altman-Z score of 7.55 indicates that CRON is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 7.55, CRON belongs to the best of the industry, outperforming 84.10% of the companies in the same industry.
There is no outstanding debt for CRON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.55
ROIC/WACCN/A
WACC9.34%
CRON Yearly LT Debt VS Equity VS FCFCRON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 24.65 indicates that CRON has no problem at all paying its short term obligations.
CRON has a better Current ratio (24.65) than 94.87% of its industry peers.
CRON has a Quick Ratio of 23.53. This indicates that CRON is financially healthy and has no problem in meeting its short term obligations.
CRON's Quick ratio of 23.53 is amongst the best of the industry. CRON outperforms 93.85% of its industry peers.
Industry RankSector Rank
Current Ratio 24.65
Quick Ratio 23.53
CRON Yearly Current Assets VS Current LiabilitesCRON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 162.50% over the past year.
CRON shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -50.78% yearly.
The Revenue has grown by 28.01% in the past year. This is a very strong growth!
The Revenue has been growing by 37.71% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)162.5%
EPS 3YN/A
EPS 5Y-50.78%
EPS Q2Q%-400%
Revenue 1Y (TTM)28.01%
Revenue growth 3Y16.47%
Revenue growth 5Y37.71%
Sales Q2Q%20.51%

3.2 Future

Based on estimates for the next years, CRON will show a very negative growth in Earnings Per Share. The EPS will decrease by -21.14% on average per year.
Based on estimates for the next years, CRON will show a small growth in Revenue. The Revenue will grow by 7.39% on average per year.
EPS Next Y-115.3%
EPS Next 2Y-15.5%
EPS Next 3Y3.91%
EPS Next 5Y-21.14%
Revenue Next Year12.95%
Revenue Next 2Y21.44%
Revenue Next 3Y7.49%
Revenue Next 5Y7.39%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CRON Yearly Revenue VS EstimatesCRON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M
CRON Yearly EPS VS EstimatesCRON Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 51.00 indicates a quite expensive valuation of CRON.
Based on the Price/Earnings ratio, CRON is valued a bit cheaper than 78.97% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.02, CRON is valued quite expensively.
The Price/Forward Earnings ratio is 35.71, which means the current valuation is very expensive for CRON.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CRON indicates a somewhat cheap valuation: CRON is cheaper than 69.74% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of CRON to the average of the S&P500 Index (22.66), we can say CRON is valued expensively.
Industry RankSector Rank
PE 51
Fwd PE 35.71
CRON Price Earnings VS Forward Price EarningsCRON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRON Per share dataCRON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.5%
EPS Next 3Y3.91%

More info and screens

0

5. Dividend

5.1 Amount

CRON does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRONOS GROUP INC

NASDAQ:CRON (9/9/2025, 4:39:12 PM)

After market: 2.54 -0.01 (-0.39%)

2.55

+0.07 (+2.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-10 2025-11-10
Inst Owners13.12%
Inst Owner Change7.8%
Ins Owners6.2%
Ins Owner Change12.24%
Market Cap976.75M
Analysts82.86
Price Target1.77 (-30.59%)
Short Float %1.4%
Short Ratio1.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-0.26%
Min Revenue beat(2)-0.31%
Max Revenue beat(2)-0.21%
Revenue beat(4)1
Avg Revenue beat(4)-1.44%
Min Revenue beat(4)-14.99%
Max Revenue beat(4)9.73%
Revenue beat(8)4
Avg Revenue beat(8)1.96%
Revenue beat(12)4
Avg Revenue beat(12)-3.07%
Revenue beat(16)7
Avg Revenue beat(16)-2.54%
PT rev (1m)0%
PT rev (3m)-33.71%
EPS NQ rev (1m)100%
EPS NQ rev (3m)N/A
EPS NY rev (1m)65.38%
EPS NY rev (3m)65.38%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.23%
Revenue NY rev (1m)-6.25%
Revenue NY rev (3m)-4.63%
Valuation
Industry RankSector Rank
PE 51
Fwd PE 35.71
P/S 7.5
P/FCF N/A
P/OCF 48.78
P/B 0.9
P/tB 0.97
EV/EBITDA N/A
EPS(TTM)0.05
EY1.96%
EPS(NY)0.07
Fwd EY2.8%
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)0.05
OCFY2.05%
SpS0.34
BVpS2.83
TBVpS2.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.57%
ROE 1.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 14.19%
GM 32.74%
FCFM N/A
ROA(3y)-5.62%
ROA(5y)-9.8%
ROE(3y)-5.87%
ROE(5y)-10.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-62.81%
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 224.14%
Cap/Sales 22.6%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 24.65
Quick Ratio 23.53
Altman-Z 7.55
F-Score7
WACC9.34%
ROIC/WACCN/A
Cap/Depr(3y)70.04%
Cap/Depr(5y)158.35%
Cap/Sales(3y)6.62%
Cap/Sales(5y)22.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)162.5%
EPS 3YN/A
EPS 5Y-50.78%
EPS Q2Q%-400%
EPS Next Y-115.3%
EPS Next 2Y-15.5%
EPS Next 3Y3.91%
EPS Next 5Y-21.14%
Revenue 1Y (TTM)28.01%
Revenue growth 3Y16.47%
Revenue growth 5Y37.71%
Sales Q2Q%20.51%
Revenue Next Year12.95%
Revenue Next 2Y21.44%
Revenue Next 3Y7.49%
Revenue Next 5Y7.39%
EBIT growth 1Y42.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year98.02%
EBIT Next 3Y27.54%
EBIT Next 5Y9.95%
FCF growth 1Y90.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y120.6%
OCF growth 3YN/A
OCF growth 5YN/A